Up-regulation of FOXD1 by YAP alleviates senescence and osteoarthritis.
Lina FuYuqiong HuMoshi SongZunpeng LiuWeiqi ZhangFa-Xing YuJun WuSi WangJuan Carlos Izpisua BelmontePiu ChanJing QuFu-Chou TangGuang-Hui LiuPublished in: PLoS biology (2019)
Cellular senescence is a driver of various aging-associated disorders, including osteoarthritis. Here, we identified a critical role for Yes-associated protein (YAP), a major effector of Hippo signaling, in maintaining a younger state of human mesenchymal stem cells (hMSCs) and ameliorating osteoarthritis in mice. Clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR associated protein 9 nuclease (Cas9)-mediated knockout (KO) of YAP in hMSCs resulted in premature cellular senescence. Mechanistically, YAP cooperated with TEA domain transcriptional factor (TEAD) to activate the expression of forkhead box D1 (FOXD1), a geroprotective protein. YAP deficiency led to the down-regulation of FOXD1. In turn, overexpression of YAP or FOXD1 rejuvenated aged hMSCs. Moreover, intra-articular administration of lentiviral vector encoding YAP or FOXD1 attenuated the development of osteoarthritis in mice. Collectively, our findings reveal YAP-FOXD1, a novel aging-associated regulatory axis, as a potential target for gene therapy to alleviate osteoarthritis.
Keyphrases
- rheumatoid arthritis
- endothelial cells
- gene therapy
- transcription factor
- mesenchymal stem cells
- knee osteoarthritis
- crispr cas
- dna damage
- genome editing
- gene expression
- poor prognosis
- binding protein
- bone marrow
- type diabetes
- cell proliferation
- long non coding rna
- risk assessment
- skeletal muscle
- adipose tissue
- immune response
- small molecule
- dna binding
- climate change
- heat shock
- protein protein